Considering its antiproliferative and pro‐apoptotic functions in early stages of carcinogenesis, we supposed that the activation of the EGFR pathway may antagonize TGF‐β‐induced antigrowth response in cancer cells, and these two pathways synergistically cooperate to increase cancer cell aggressiveness. This evidence concerns the gene TGFB1 and cancer.